Business · 1 sources covering this

Delhi HC restrains Zydus from launching Dabrafenib till patent expiry

Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis' Indian patent expires in May 2029; statutory Bolar rights remain protected

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·1h ago
Delhi HC restrains Zydus from launching Dabrafenib till patent expiry
Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis' Indian patent expires in May 2029; statutory Bolar rights remain protected
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/558162f224ece8cdcb1ca708b7861b684e887f8a"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Delhi HC restrains Zydus from launching Dabrafenib till patent expiry"></iframe>

Delhi HC restrains Zydus from launching Dabrafenib till patent expiry

How 1 sources are covering this

Delhi HC restrains Zydus from launching Dabrafenib till patent expiry

More from Business

Top Indian ministers to hold talks in Singapore

Income Tax Dept investigates outward remittances; shell entities, CSR expenses under scanner

Trump called ballots ‘inherently corrupt’, then voted by mail in Florida primary 2026

US Elections Tuesday: Florida, Alaska, Wyoming Primaries, California Special Election — Key contests to watch

Reader

Trust & legal

Across the network